Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?
about
The role of magnetic resonance imaging in the diagnosis and management of prostate cancerProstate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging.Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy.The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancerMRI for men undergoing active surveillance or with rising PSA and negative biopsies.Mapping of prostate cancer by 1H MRSI.Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis.Image-based monitoring of targeted biopsy-proven prostate cancer on active surveillance: 11-year experience.Magnetic resonance spectroscopic imaging of benign prostatic tissue: findings at 3.0 T compared to 1.5 T-initial experience.An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy.Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance.Can high-spatial resolution T2-weighted endorectal MRI rule out clinically significant prostate cancer?Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance.[The relevance of magnetic resonance imaging (MRI) for the detection and exclusion of prostate cancer].
P2860
Q26849794-753F23E5-6C50-4768-9C0B-E27D47A1E314Q33964345-91B6A240-B124-4BA3-855E-0D3940DA0863Q37331924-D6828DC0-BF31-4F2B-B42F-F6A72FA8CA9EQ37372799-80C7D3AA-504C-442E-AF95-E57A00538587Q37709638-A9AABF6D-54CA-4468-88D4-A8DBF81BF860Q37798723-531D878E-B3B0-4DF3-A947-C70D5EC12C8FQ38114017-1C17F7A6-81E7-44C2-8484-C280491F7D2AQ38489794-C3278CFD-01B2-4A20-A4AE-DBA1817BAC53Q38993533-8BD607CA-520B-4424-9712-865D44CD3E19Q41923641-80ECFCBE-FEF5-44DF-B4F9-1819B5FDAE84Q42047146-7037300A-68A5-494A-9C70-4769D3DFE08AQ42907440-E21E9522-8D9B-4714-8BDB-31BF8F532078Q43428500-013A7BFE-A171-4635-9B58-96D5C6B548D2Q45757477-BB30D4D3-A7BF-41CE-829D-E6E4D9F9ED41Q53308886-7679E055-14AE-4143-96DE-48D248ABF97E
P2860
Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Prostate cancer: is inapparent ...... ho select active surveillance?
@en
Prostate cancer: is inapparent ...... ho select active surveillance?
@nl
type
label
Prostate cancer: is inapparent ...... ho select active surveillance?
@en
Prostate cancer: is inapparent ...... ho select active surveillance?
@nl
prefLabel
Prostate cancer: is inapparent ...... ho select active surveillance?
@en
Prostate cancer: is inapparent ...... ho select active surveillance?
@nl
P2093
P2860
P1433
P1476
Prostate cancer: is inapparent ...... ho select active surveillance?
@en
P2093
Alvin R Cabrera
Antonio C Westphalen
Fergus V Coakley
John Kurhanewicz
Katsuto Shinohara
Peter R Carroll
Shoujun Zhao
P2860
P304
P356
10.1148/RADIOL.2472070770
P407
P577
2008-05-01T00:00:00Z